Wei-Hsuan “Jenny” Lo-Ciganic, M.S.Pharm, M.S., Ph.D. joined the University of Florida College of Pharmacy, department of pharmaceutical outcomes and policy as an assistant professor in 2018. She is a pharmacoepidemiologist, with research interests in drug safety, medication adherence, prescription drug abuse and quality and value of prescribing, especially among vulnerable or minority populations. Her interests in patient safety and quality of care issues focus on improving and developing quality measures and prediction tools using advanced analytics (e.g., machine learning).
Prior to arriving at the University of Florida, Lo-Ciganic worked as an assistant professor at the University of Arizona College of Pharmacy from 2015-18. She was a recipient of the 2015 University of Arizona Health Science Career Development Award and 2016 American Association of Colleges of Pharmacy New Investigator Award. In 2017, Lo-Ciganic received the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Award in Health Outcomes. Recently she became the Co-Pi for the R01 project, “Using Machine Learning to Predict Problematic Opioid Use”, in two large state Medicaid programs, which has been funded by the National Institute of Drug Abuse (NIDA). Since 2015, she has been a member and co-chair of the Pharmacy Quality Alliance’s (PQA) workgroups and Quality Metrics Expert Panel to develop and improve quality measures of prescription medications.
- Ph.D., Epidemiology, University of Pittsburgh, Pittsburgh, USA
- M.S., Biostatistics, University of Pittsburgh, Pittsburgh, USA
- M.S., Clinical Pharmacy, National Cheng-Kung University, Tainan, Taiwan
- B.S., Pharmacy with a minor in Horticulture, National Taiwan University, Taipei, Taiwan
- International Society for Pharmacoepidemiology (ISPE)
- International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
- American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP)
- Pharmaceutical health service research
- Patient safety, quality of prescribing and care, program and policy evaluation
- Medication adherence
- Prescription drug abuse and substance use disorders
- Advanced analytics including trajectory analysis, machine learning, and spatial pattern mining
- Cochran G, Lo-Ciganic W, Gellad WF, Gordon AJ, Cole E, Chang C, Lobo C, Frazier W, Zheng P, Chang, C-C, Kelley D, Donohue JM. Prescription Opioid Quality Measures Applied among Pennsylvania Medicaid Enrollees. J Manag Care Spec Pharm 2018 (in press).
- Anderson TS, Lo-Ciganic W, Gellad WF, Zhang R, Huskamp HA, Choudhry NK, Chang C-H, Richards-Shubik S, Guclu H, Donohue JM. Physician adoption of new cardiovascular drugs: characteristics of rapid adopters and conservative prescribers. Healthc (Amst). 2017 Oct 21.PMID: 29066168. DOI: 10.1016/j.hjdsi.2017.09.004.
- Hill MG, Gonzalez MG, Lo-Ciganic W, Reed KL. Misoprostol in addition to a double balloon catheter for induction: A double-blind randomized controlled trial. Am J Perinatol. 2017 Sep 14. PMID: 28910848. DOI: 10.1055/s-0037-1606606.
- Frazier W, Cochran G, Lo-Ciganic W, Gellad WF, Gordon AJ, Chang CC, Donohue JM. Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid. JAMA 2017; 318(8):750-752. PMID: 28829862. DOI: 10.1001/jama.2017.7818
- Cochran G, Gordon AJ, Gellad WF, Chang C-C, Lo-Ciganic W, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue JM. Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care. 2017; 23(5):e164-e171 PMID: 28810127
- Almutairi A, Zhou L, Gellad WF, Lee JK, Slack M, Martin JR, Lo-Ciganic W. Effectiveness and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation or venous thromboembolism: systematic review and meta-analyses. Clin Ther 2017 Jun 28. PMID: 28668628 DOI: 10.1016/j.clinthera.2017.05.358
- Lo-Ciganic W, Floden L, Lee JK, Ashbeck EL, Zhou L*, Chinthammit C*, Purdy AW, Kwoh CK, Patterns of analgesic use and risk of recurrent falls in patients with- or at-risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthr Cartil 2017; 25:1390-1398. PMID: 28385483. DOI: 10.1016/j.joca.2017.03.017
- Cochran G, Gordon AJ, Lo-Ciganic W, Gellad WF, Frazier W, Lobo C, Zheng P, Donohue JM. An examination of claims-based predictors of overdose from a large Medicaid program. Med Care. 2017; 55:291-298. PMCID: PMC5309160. DOI: 10.1097/MLR.0000000000000676
- Lo-Ciganic W, Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, Marcum ZA, Gellad WF. Trajectories of diabetes medication adherence and hospitalization risk. J Gen Intern Med. 2016; 31:1052-60. PMCID: PMC4978686. DOI:10.1007/s11606-016-3747-6
- Gordon AJ, Lo-Ciganic W, Cochran G, Gellad WF, Cathers T, Donohue JM. Treatment quality for buprenorphine care: The pot at the end of the rainbow. [In Reply to “Measurement Quality of Buprenorphine Care”]. J Addict Med. 2016;10:210-1. PMID: 27223837. DOI: 10.1097/ADM. 0000000000000210
- Lo-Ciganic W, Gellad WF, Huskamp HA, Choudhry NK, Chang CH, Zhang R, Jones BL, Guclu H, Richards-Shubik S, Donohue JM. Who were the early adopters of dabigatran? An application of group-based trajectory models. Med Care 2016; 54:725-32. PMCID: PMC4907845. DOI: 10.1097/MLR.0000000000000549